| Pauline Funchain, MD | |
|
300 Pasteur Dr, Palo Alto, CA 94304-2203 | |
| (650) 723-4000 | |
| Not Available |
| Full Name | Pauline Funchain |
|---|---|
| Gender | Female |
| Speciality | Medical Oncology |
| Experience | 18 Years |
| Location | 300 Pasteur Dr, Palo Alto, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730371832 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stanford Health Care | Stanford, CA | Hospital |
| Cleveland Clinic | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stanford Health Care | 6709797491 | 2572 |
News Archive
The level of physical activity displayed by an elderly individual with chronic low back pain is a better predictor for functional capacity than psychosocial factors, results from a community-based study indicate.
While the world knows the $3 billion California Institute for Regenerative Medicine sprang from the citizen's initiative, Proposition 71, few people know the struggle required, nor what happened after California said "Yes!"
PKU is described by scientists as an autosomal recessive genetic disease that is characterized by a deficiency in an enzyme called phenylalanine hydroxylase (PAH).
By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
› Verified 7 days ago
| Entity Name | Stanford Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437292927 PECOS PAC ID: 6709797491 Enrollment ID: O20031124000348 |
News Archive
The level of physical activity displayed by an elderly individual with chronic low back pain is a better predictor for functional capacity than psychosocial factors, results from a community-based study indicate.
While the world knows the $3 billion California Institute for Regenerative Medicine sprang from the citizen's initiative, Proposition 71, few people know the struggle required, nor what happened after California said "Yes!"
PKU is described by scientists as an autosomal recessive genetic disease that is characterized by a deficiency in an enzyme called phenylalanine hydroxylase (PAH).
By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
› Verified 7 days ago
| Entity Name | Lpch Medical Group Div Of Lucile |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417907940 PECOS PAC ID: 0840298543 Enrollment ID: O20061113000232 |
News Archive
The level of physical activity displayed by an elderly individual with chronic low back pain is a better predictor for functional capacity than psychosocial factors, results from a community-based study indicate.
While the world knows the $3 billion California Institute for Regenerative Medicine sprang from the citizen's initiative, Proposition 71, few people know the struggle required, nor what happened after California said "Yes!"
PKU is described by scientists as an autosomal recessive genetic disease that is characterized by a deficiency in an enzyme called phenylalanine hydroxylase (PAH).
By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pauline Funchain, MD 300 Pasteur Dr, Palo Alto, CA 94304-2203 Ph: (650) 723-4000 | Pauline Funchain, MD 300 Pasteur Dr, Palo Alto, CA 94304-2203 Ph: (650) 723-4000 |
News Archive
The level of physical activity displayed by an elderly individual with chronic low back pain is a better predictor for functional capacity than psychosocial factors, results from a community-based study indicate.
While the world knows the $3 billion California Institute for Regenerative Medicine sprang from the citizen's initiative, Proposition 71, few people know the struggle required, nor what happened after California said "Yes!"
PKU is described by scientists as an autosomal recessive genetic disease that is characterized by a deficiency in an enzyme called phenylalanine hydroxylase (PAH).
By employing optogenetics, a new field that uses genetically altered cells to respond to light, and a tandem unit cell (TCU) strategy, researchers at Stony Brook University have demonstrated a way to control cell excitation and contraction in cardiac muscle cells, the details of which are published in the early online edition of Circulation: Arrhythmia & Electrophysiology: "Stimulating Cardiac Muscle by Light: Cardiac Optogenetics by Cell Delivery."
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
› Verified 7 days ago
Daniel Joseph Razzano, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Mahnoosh Kuhbanani Seifoddini, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Va Palo Alto Health Care System (111stc), Palo Alto, CA 94304 Phone: 209-946-3400 | |
Dr. Yusra Nazar Hussain, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 770 Welch Rd, Suite # 250, Palo Alto, CA 94304 Phone: 650-328-1676 Fax: 650-445-0911 | |
Dr. David Yao, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Medical Services (111a), Palo Alto, CA 94304 Phone: 650-493-5000 | |
Dr. Franklin Perry, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2175 Park Blvd, Palo Alto, CA 94306 Phone: 650-330-3688 Fax: 650-330-3686 | |
Dr. Ryan Arthur Mcconnell, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-853-2972 | |
Dr. Ann Margaretha Lowe, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 420 Cambridge Ave, Unit 3, Palo Alto, CA 94306 Phone: 650-323-6614 |